Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turning FDA's 'Clunky' Drug Database Into A Useable Goldmine

Executive Summary

The FDA's drug database, Drugs@FDA, is a goldmine of information. Unfortunately, because of the agency's "clunky" website, the data are difficult to access, search and aggregate, so the information's value is largely lost. But a group of scientists are using an $80,000 Open Science Prize to try to change that aggravating situation.

You may also be interested in...



US Capitol Capsule: Cancer Therapies, Orphan Drugs Dominated 2015 Approvals; PCSK9s Arrived

Cancer therapies dominated US drug approvals in 2015, with the FDA's Center for Drug Evaluation and Research (CDER) also giving its nod to a record number of medicines that had gained orphan drug designation.

US Capitol Capsule: 2014: a year for orphan drugs, anti-PD-1s, 2nd chancers

The FDA's Center for Drug Evaluation and Research (CDER) in 2014 had its best year in drug approvals since 1996 – clearing 41 new molecular entities (NMEs) and novel biologics over the past 12 months.

2013 was springboard for 'breakthrough' drugs

While the FDA's Center for Drug Evaluation and Research (CDER) approved 12 fewer new molecular entities (NMEs) and new therapeutic biologics in 2013 than it did in 2012 – 27 versus 39, respectively – the past year served as a springboard for the agency's new breakthrough therapy designation, with three medicines with the new status among the products gaining the agency's blessing to enter the US market.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel